A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2022-10-15
Target enrollment:
Participant gender:
Summary
TAK-981 is being tested in combination with pembrolizumab to treat participants who have
select advanced or metastatic solid tumors.
The study aims are to evaluate the safety, tolerability, and preliminary efficacy of TAK-981
in combination with pembrolizumab.
Participants will be on this combination treatment for 21-day cycles. They will continue with
this treatment for up to 24 months or until participants meet any discontinuation criteria.